Skip to content

Precigen PGEN Return on equity

Return on equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
38.8%+7.3pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
14.5%-1.4pp
Gilead Sciences logo
Gilead SciencesGILD
43.2%+10.7pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-58.1%+7.9pp
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-32.8%
Arrowhead Research logo
Arrowhead ResearchARWR
-46.4%+341pp

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Calculated from Precigen’s reported figures.

Based on trailing twelve months.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's return on equity?
Precigen (PGEN) reported return on equity of -843.6% in Q4 2025.
How has Precigen's return on equity changed year-over-year?
Precigen's return on equity decreased by 424.6% year-over-year, from -160.8% to -843.6%.
What is the long-term trend for Precigen's return on equity?
Over 4 years (2020 to 2025), Precigen's return on equity has grown at a 36.1% compound annual growth rate (CAGR), from -245.6% to -843.6%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.